natgillin/translations-raw huggingface dataset:
happens after you have been given OLANZAPINE NEOPHARMA tell your doctor.
se vam to zgodi po tem, ko ste prejeli zdravilo OLANZAPIN NEOPHARMA, povejte svojemu zdravniku.
- Very rarely, medicines of this type cause a combination of fever, faster breathing, sweating,
- Zelo redko tovrstna zdravila povzročijo kombinacijo zvišanja telesne temperature, pospešenega
- The use of OLANZAPINE NEOPHARMA in elderly patients with dementia is not
- Uporabe zdravila OLANZAPIN NEOPHARMA pri starejših bolnikih z demenco ne
recommended as it may have serious side effects.
priporočamo, ker ima lahko resne neželene učinke.
• Diabetes • Heart disease • Liver or kidney disease • Parkinson’ s disease • Epilepsy • Prostate problems • A blocked intestine (Paralytic ileus) • Blood disorders • Stroke or “ mini” stroke (temporary symptoms of stroke)
• sladkorno bolezen • srčno obolenje • obolenje jeter ali ledvic • Parkinsonovo bolezen • epilepsijo • težave s prostato • zaporo črevesa (paralitični ileus) • bolezni krvi • možgansko kap ali » majhno « možgansko kap (prehodni znaki kapi)
OLANZAPINE NEOPHARMA is not for patients who are under 18 years.
Zdravilo OLANZAPIN NEOPHARMA ni namenjeno bolnikom, mlajšim od 18 let.
Taking other medicines Only take other medicines while you are on OLANZAPINE NEOPHARMA if your doctor tells you that you can.
Jemanje drugih zdravil Med zdravljenjem z zdravilom OLANZAPIN NEOPHARMA jemljite druga zdravila samo, če vam zdravnik pove, da smete.
You might feel drowsy if OLANZAPINE NEOPHARMA is taken in combination with antidepressants or medicines taken for anxiety or to help you sleep (tranquillisers).
Če jemljete zdravilo OLANZAPIN NEOPHARMA v kombinaciji z zdravili za zdravljenje depresije, zdravili za zdravljenje občutkov tesnobe ali zdravili, ki vam pomagajo spati (pomirjevala), se lahko počutite zaspani.
You should tell your doctor if you are taking fluvoxamine (an antidepressant) or ciprofloxacin (an antibiotic), as it may be necessary to change your OLANZAPINE NEOPHARMA dose.
Če jemljete fluvoksamin (zdravilo za zdravljenje depresije) ali ciprofloksacin (antibiotik), morate povedati svojemu zdravniku, ker bo morda treba spremeniti vaš odmerek zdravila OLANZAPIN NEOPHARMA.
Taking OLANZAPINE NEOPHARMA with food and drink Do not drink any alcohol if you have been given OLANZAPINE NEOPHARMA as OLANZAPINE NEOPHARMA and alcohol together may make you feel drowsy.
Jemanje zdravila OLANZAPIN NEOPHARMA skupaj s hrano in pijačo Če ste dobili zdravilo OLANZAPIN NEOPHARMA, ne pijte nobenega alkohola, saj lahko zdravilo OLANZAPIN NEOPHARMA in alkohol skupaj povzročita občutek zaspanosti.
Pregnancy and breast-feeding Tell your doctor as soon as possible if you are pregnant or think you may be pregnant.
Nosečnost in dojenje Čimprej povejte svojemu zdravniku, če ste noseči ali mislite, da bi lahko bili noseči.
You should not be given this medicine when breast-feeding, as small amounts of OLANZAPINE NEOPHARMA can pass into breast milk.
Ko dojite, tega zdravila ne smete jemati, ker lahko majhne količine zdravila OLANZAPIN NEOPHARMA prehajajo v materino mleko.
Driving and using machines There is a risk of feeling drowsy when you are given OLANZAPINE NEOPHARMA.
Vpliv na sposobnost upravljanja vozil in strojev Obstaja tveganje, da se boste po tem, ko ste dobili zdravilo OLANZAPIN NEOPHARMA, počutili zaspane.
Important information about some of the ingredients of OLANZAPINE NEOPHARMA OLANZAPINE NEOPHARMA contains lactose.
Pomembne informacije o nekaterih sestavinah zdravila OLANZAPIN NEOPHARMA Zdravilo OLANZAPIN NEOPHARMA vsebuje laktozo.
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.
Če vam je vaš zdravnik povedal, da imate 93 intoleranco za nekatere sladkorje, se pred jemanjem tega zdravila posvetujte s svojim zdravnikom.
HOW TO TAKE OLANZAPINE NEOPHARMA
KAKO JEMATI ZDRAVILO OLANZAPIN NEOPHARMA
Always take OLANZAPINE NEOPHARMA exactly as your doctor has told you.
Pri jemanju zdravila OLANZAPIN NEOPHARMA natančno upoštevajte zdravnikova navodila.
Your doctor will tell you how many OLANZAPINE NEOPHARMA tablets to take and how long you should continue to take them.
Zdravnik vam bo povedal, koliko OLANZAPIN NEOPHARMA tablet morate vzeti in kako dolgo naj bi jih jemali.
The daily dose of OLANZAPINE NEOPHARMA is between 5 and 20 mg.
Dnevni odmerek zdravila OLANZAPIN NEOPHARMA je med 5 in 20 mg.
Consult your doctor if your symptoms return but do not stop taking OLANZAPINE NEOPHARMA unless your doctor tells you to.
Če se simptomi povrnejo, se posvetujte s svojim zdravnikom, vendar ne prenehajte jemati zdravila OLANZAPIN NEOPHARMA, če vam tega ne naroči vaš zdravnik.
You should take your OLANZAPINE NEOPHARMA tablets once a day following the advice of your doctor.
OLANZAPIN NEOPHARMA tablete jemljite enkrat na dan, in sicer upoštevajte nasvet zdravnika.
OLANZAPINE NEOPHARMA coated tablets are for oral use.
OLANZAPIN NEOPHARMA obložene tablete so za peroralno uporabo.
You should swallow the OLANZAPINE NEOPHARMA tablets whole with water.
OLANZAPIN NEOPHARMA tablete pogoltnite cele z vodo.
If you take more OLANZAPINE NEOPHARMA than you should Patients who have taken more OLANZAPINE NEOPHARMA than they should, have experienced the following symptoms: rapid beating of the heart, agitation/ aggressiveness, problems with speech, unusual movements (especially of the face or tongue) and reduced level of consciousness.
Če ste vzeli večji odmerek zdravila OLANZAPIN NEOPHARMA, kot bi smeli Bolniki, ki so vzeli večji odmerek zdravila OLANZAPIN NEOPHARMA, kot bi smeli, so imeli naslednje simptome: hitro bitje srca, vznemirjenost/ nasilnost, težave pri govoru, nenavadne zgibke (posebno v mišicah obraza ali jezika) in zmanjšano stopnjo zavesti.
If you forget to take OLANZAPINE NEOPHARMA Take your tablets as soon as you remember.
Če ste pozabili vzeti zdravilo OLANZAPIN NEOPHARMA Vzemite tablete, kakor hitro se spomnite.
If you stop taking OLANZAPINE NEOPHARMA Do not stop taking your tablets just because you feel better.
Če ste prenehali jemati zdravilo OLANZAPIN NEOPHARMA Ne prenehajte jemati tablet samo zato, ker se počutite bolje.
It is important that you carry on taking OLANZAPINE NEOPHARMA for as long as your doctor tells you.
Pomembno je, da nadaljujete z jemanjem zdravila OLANZAPIN NEOPHARMA tako dolgo, kot vam naroči zdravnik.
If you suddenly stop taking OLANZAPINE NEOPHARMA, symptoms such as sweating, unable to sleep, tremor, anxiety or nausea and vomiting might occur.
Če nenadno prenehate jemati zdravilo OLANZAPIN NEOPHARMA, se lahko pojavijo simptomi, kot so znojenje, nespečnost, tresenje, občutek tesnobe ali slabost in bruhanje.
Like all medicines, OLANZAPINE NEOPHARMA can cause side effects, although not everybody gets them.
Kot vsa zdravila ima lahko tudi zdravilo OLANZAPIN NEOPHARMA neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
95 • Tremor. • Muscle stiffness or spasm (including eye movements). • Problems with speech. • Unusual movement (especially of the face or tongue). • Constipation. • Dry mouth. • Rash. • Loss of strength. • Extreme tiredness. • Water retention leading to swelling of the hands, ankles or feet. • In the early stages of treatment, some people may feel dizzy or faint (with a slow heart rate), especially when getting up from a lying or sitting position.
Pogosti neželeni učinki: pri 1 do 10 uporabnikov od 100 • spremembe v ravneh nekaterih krvnih celic in maščob v krvnem obtoku • zvišanja v ravni sladkorjev v krvi in urinu • večji občutek lakote • omotica • nemirnost 94 • tresenje • mišična okorelost ali krči (vključno z obračanjem zrkel) • težave pri govoru • nenavadni zgibki (posebno v mišicah obraza ali jezika) • zaprtje • suha usta • izpuščaj • izguba moči • huda utrujenost • zadrževanje vode, ki vodi v otekanje rok, gležnjev ali nog • Nekateri ljudje imajo lahko v začetnih obdobjih zdravljenja občutek omotice ali oslabelosti (z upočasnjenim srčnim utripom), zlasti pri vstajanju iz ležečega ali sedečega položaja.
In patients with Parkinson's disease OLANZAPINE NEOPHARMA may worsen the symptoms.
Pri bolnikih s Parkinsonovo boleznijo lahko zdravilo OLANZAPIN NEOPHARMA poslabša simptome.
Very rarely babies born to mothers who have taken OLANZAPINE NEOPHARMA in the last stage of pregnancy (3rd trimester) may have tremors, be sleepy or drowsy.
Zelo redko se lahko dojenčki, rojeni materam, ki so jemale zdravilo OLANZAPIN NEOPHARMA v zadnjem, tretjem trimesečju nosečnosti, tresejo, so zaspani ali dremavi.
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor.
Če katerikoli neželeni učinek postane resen ali če opazite katerikoli neželeni učinek, ki ni omenjen v
HOW TO STORE OLANZAPINE NEOPHARMA COATED TABLETS 96 Keep out of the reach and sight of children.
SHRANJEVANJE ZDRAVILA OLANZAPIN NEOPHARMA
Do not use Olanzapine Neopharma after the expiry date which is stated on the carton after Exp.
Zdravila OLANZAPIN NEOPHARMA ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli.
What Olanzapine Neopharma contains
Kaj vsebuje zdravilo OLANZAPIN NEOPHARMA
Each Olanzapine Neopharma coated tablet contains either
Vsaka obložena tableta zdravila OLANZAPIN
2.5 mg, 5 mg, 7.5 mg, 10 mg or 15 mg of the active substance.
NEOPHARMA vsebuje 2, 5 mg, 5 mg, 7, 5 mg, 10 mg ali 15 mg zdravilne učinkovine.
- Tablet core: lactose monohydrate (See also end of section 2 – important information about some
- Jedro tablete: laktoza monohidrat (glejte tudi konec 2. poglavja – pomembne informacije o
of the ingredients of Olanzapine Neopharma), maize starch, hydroxypropyl cellulose, magnesium stearate.
nekaterih sestavinah zdravila OLANZAPIN NEOPHARMA), koruzni škrob, hidroksipropilceluloza, magnezijev stearat.
- Tablet coat:
- Obloga tablete:
- 2.5 mg, 5 mg, 7.5 mg and 10 mg tablets:
- 2, 5 mg, 5 mg, 7, 5 mg in 10 mg tablete:
Opadry white containing hypromellose (E464),
Opadry beli, ki vsebuje hipromelozo (E464), titanov
titanium dioxide (E171), lactose monohydrate, polyethylene glycol 3000 and glycerol triacetate
dioksid (E171), laktozo monohidrat, makrogol 3000 in gliceriltriacetat
- 15 mg tablets:
- 15 mg tablete:
Opadry Blue containing hypromellose (E464), titanium dioxide (E171),
Opadry modri, ki vsebuje hipromelozo (E464), titanov dioksid (E171), laktozo
polyethylene glycol 6000, indigo carmine aluminium lake (E132), brilliant blue FCF aluminium lake (E133) and iron oxide black (E172)
monohidrat, makrogol 6000, barvilo indigotin (E132), barvilo modro FCF (E133) in črni železov oksid (E172)
What OLANZAPINE NEOPHARMA looks like and contents of the pack Olanzapine Neopharma 2.5 mg coated tablets are white, round, biconvex, coated tablets with ‘ 2.5’ debossed on one side and ‘ OLZ’ on the other.
Izgled OLANZAPIN NEOPHARMA in vsebina pakiranja OLANZAPIN NEOPHARMA 2, 5 mg obložene tablete so bele, okrogle, bikonveksne, obložene tablete z vtisnjeno oznako '2, 5' na eni strani in 'OLZ' na drugi.
Olanzapine Neopharma 5 mg coated tablets are white, round, biconvex, coated tablets with ‘ OLZ 5’ debossed on one side and ‘ NEO’ on the other.
OLANZAPIN NEOPHARMA 5 mg obložene tablete so bele, okrogle, bikonveksne, obložene tablete z vtisnjeno oznako 'OLZ' na eni strani in 'NEO' na drugi.
Olanzapine Neopharma 7.5 mg coated tablets are white, round, biconvex, coated tablets with ‘ OLZ 7.5’ debossed on one side and ‘ NEO’ on the other.
OLANZAPIN NEOPHARMA 7, 5 mg obložene tablete so bele, okrogle, bikonveksne, obložene tablete z vtisnjeno oznako 'OLZ 7, 5' na eni strani in 'NEO' na drugi.
Olanzapine Neopharma 10 mg coated tablets are white, round, biconvex, coated tablets with ‘ OLZ 10’ debossed on one side and ‘ NEO’ on the other.
OLANZAPIN NEOPHARMA 10 mg obložene tablete so bele, okrogle, bikonveksne, obložene tablete z vtisnjeno oznako 'OLZ 10' na eni strani in 'NEO' na drugi.
Olanzapine Neopharma 15 mg coated tablets are blue, elliptical, convex, coated tablets with ‘ NEO’ debossed on one side and plain on the other side.
OLANZAPIN NEOPHARMA 15 mg obložene tablete so modre, okrogle, eliptične, obložene tablete z vtisnjeno oznako 'NEO' na eni in brez oznake na drugi strani.
Olanzapine Neopharma 2.5 mg, 5 mg, 7.5 mg and 15 mg coated tablets are available in 28 and 56 blister packs.
OLANZAPIN NEOPHARMA 2, 5 mg, 5 mg, 7, 5 mg in 15 mg obložene tablete so na voljo v pakiranjih po 28 in 56 tablet.
Olanzapine Neopharma 10 mg coated tablets are available in 7, 28 and 56 blister packs.
OLANZAPIN NEOPHARMA 10 mg obložene tablete so na voljo v pakiranjih po 7, 28 in 56 tablet.
97 Marketing Authorisation Holder and Manufacturer
96 Imetnik dovoljenja za promet z zdravilom in izdelovalec
Neopharma Limited, 57 High Street, Odiham, Hampshire, RG29 1LF, UK Tel: +44 (0)1256 704110 Fax: +44 (0)1256 701144
Neopharma Limited, 57 High Street, Odiham, Hampshire, RG29 1LF, Veľká Británia Tel: +44 (0) 1256 704110 Fax: +44 (0) 1256 701144 Izdelovalec:
This leaflet was last approved in {MM/ YYYY}.
Navodilo je bilo odobreno dne {MM/ YYYY}.
15 mg; pink and oval:
15 mg; rožnatih in ovalnih:
20 mg) and as round ‘ orodispersible’ tablets (yellow:
20 mg) in v obliki „ orodisperzibilnih “ tablet (rumene barve:
5 and 10 mg; orange:
5 in 10 mg; oranžne barve:
15 mg; green:
15 mg; zelene barve:
Olanzapine Teva is a ‘ generic medicine’.
Olanzapine Teva je „ generično zdravilo “.
This means that Olanzapine Teva is similar to ‘ reference medicines’ already authorised in the European Union (EU) called Zyprexa and Zyprexa Velotab.
To pomeni, da je podobno „ referenčnima zdraviloma “, ki sta že odobreni v Evropski uniji (EU), in sicer zdravilu Zyprexa in zdravilu Zyprexa Velotab.
Olanzapine Teva is used to treat adults with schizophrenia.
Zdravilo Olanzapine Teva se uporablja za zdravljenje odraslih s shizofrenijo.
Olanzapine Teva is also used to treat moderate to severe manic episodes (extremely high mood) in adults.
Zdravilo Olanzapine Teva se uporablja tudi za zdravljenje zmernih do težkih maničnih epizod (izjemno privzdignjenega razpoloženja) pri odraslih.
10 mg per day is used in schizophrenia and in the prevention of manic episodes, and 15 mg per day in the treatment of manic episodes, unless it is used with other medicines, in which case the starting dose can be 10 mg per day.
Priporočeni začetni odmerek zdravila Olanzapine Teva je odvisen od bolezni, ki jo zdravimo: odmerek 10 mg na dan se uporablja pri shizofreniji in za preprečevanje maničnih epizod, odmerek 15 mg na dan pa se uporablja pri zdravljenju maničnih epizod, razen v primeru sočasne uporabe z drugimi zdravili, ko lahko začetni odmerek znaša 10 mg na dan.
It is known as an ‘ atypical’ antipsychotic because it is different from the older antipsychotic medicines that have been available since the 1950s.
Spada med „ atipične “ antipsihotike, ker se razlikuje od starejših antipsihotikov, ki so na voljo že od petdesetih let minulega stoletja.
Because Olanzapine Teva is a generic medicine, studies have been limited to tests to demonstrate that it is bioequivalent to the reference medicines (i. e. that the medicines produce the same levels of the active substance in the body).
Ker je zdravilo Olanzapine Teva generično zdravilo, so bile študije omejene na teste, s katerimi se lahko dokaže, da je bioekvivalentno referenčnima zdraviloma (to pomeni, da omenjena zdravila dosegajo enake ravni zdravilne učinkovine v telesu).
What are the benefit and risk of Olanzapine Teva?
Kakšne so koristi in tveganja, povezana z zdravilom Olanzapine Teva?
Because Olanzapine Teva is a generic medicine and is bioequivalent to the reference medicines, its benefit and risk are taken as being the same as those of the reference medicines.
Ker je Olanzapine Teva generično zdravilo in je biološko enakovredno referenčnima zdraviloma, se domneva, da ima enake koristi in tveganja kot referenčni zdravili.
The Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Olanzapine Teva has been shown to have comparable quality and to be bioequivalent to Zyprexa and Zyprexa Velotab.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v s skladu z zahtevami EU dokazano, da ima zdravilo Olanzapine Teva primerljivo raven kakovosti kot zdravili Zyprexa in Zyprexa Velotab ter da je njun bioekvivalent.
Therefore, the CHMP’ s view was that, as for Zyprexa and Zyprexa Velotab, the benefit outweighs the identified risk.
Zaradi tega je CHMP menil, da koristi zdravila Olanzapine Teva tako kot pri zdravilih Zyprexa in Zyprexa Velotab odtehtajo znana tveganja.
The Committee recommended that Olanzapine Teva be given marketing authorisation.
Odbor je priporočil, da se za zdravilo Olanzapine Teva odobri dovoljenje za promet.
Other information about Olanzapine Teva:
Druge informacije o zdravilu Olanzapine Teva:
The European Commission granted a marketing authorisation valid throughout the EU for Olanzapine Teva to Teva Pharma BV on 12 December 2007.
Evropska komisija je dovoljenje za promet z zdravilom Olanzapine Teva, veljavno po vsej Evropski uniji, odobrila družbi Teva Pharma BV dne 12. decembra 2007.
The full EPAR for Olanzapine Teva can be found here.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Olanzapine Teva je na voljo tukaj.
The full EPARs for the reference medicines can also be found on the EMEA’ s website.
Celotno evropsko javno poročilo o oceni zdravila za referenčni zdravili je na voljo na spletni strani agencije EMEA.
Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva
Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva
Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Orodispersible tablet Orodispersible tablet Orodispersible tablet Orodispersible tablet Orodispersible tablet Orodispersible tablet Orodispersible tablet Orodispersible tablet Orodispersible tablet Orodispersible tablet Orodispersible tablet Orodispersible tablet Orodispersible tablet Orodispersible tablet Orodispersible tablet
Filmsko obložene tablete Filmsko obložene tablete Filmsko obložene tablete Filmsko obložene tablete Filmsko obložene tablete Filmsko obložene tablete Filmsko obložene tablete Filmsko obložene tablete Filmsko obložene tablete Filmsko obložene tablete Filmsko obložene tablete Filmsko obložene tablete Filmsko obložene tablete Filmsko obložene tablete Filmsko obložene tablete Filmsko obložene tablete Filmsko obložene tablete Filmsko obložene tablete Filmsko obložene tablete Filmsko obložene tablete Filmsko obložene tablete Filmsko obložene tablete Orodisperzibilne tablete Orodisperzibilne tablete Orodisperzibilne tablete Orodisperzibilne tablete Orodisperzibilne tablete Orodisperzibilne tablete Orodisperzibilne tablete Orodisperzibilne tablete Orodisperzibilne tablete Orodisperzibilne tablete Orodisperzibilne tablete Orodisperzibilne tablete Orodisperzibilne tablete Orodisperzibilne tablete Orodisperzibilne tablete
Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use
za peroralno uporabo za peroralno uporabo za peroralno uporabo za peroralno uporabo za peroralno uporabo za peroralno uporabo za peroralno uporabo za peroralno uporabo za peroralno uporabo za peroralno uporabo za peroralno uporabo za peroralno uporabo za peroralno uporabo za peroralno uporabo za peroralno uporabo za peroralno uporabo za peroralno uporabo za peroralno uporabo za peroralno uporabo za peroralno uporabo za peroralno uporabo za peroralno uporabo za peroralno uporabo za peroralno uporabo za peroralno uporabo za peroralno uporabo za peroralno uporabo za peroralno uporabo za peroralno uporabo za peroralno uporabo za peroralno uporabo za peroralno uporabo za peroralno uporabo za peroralno uporabo za peroralno uporabo za peroralno uporabo za peroralno uporabo
blister (OPA/ Al/ PVC/ Al) blister (OPA/ Al/ PVC/ Al) blister (OPA/ Al/ PVC/ Al) blister (OPA/ Al/ PVC/ Al) blister (OPA/ Al/ PVC/ Al) blister (OPA/ Al/ PVC/ Al) blister (OPA/ Al/ PVC/ Al) blister (OPA/ Al/ PVC/ Al) blister (OPA/ Al/ PVC/ Al) blister (OPA/ Al/ PVC/ Al) blister (OPA/ Al/ PVC/ Al) blister (OPA/ Al/ PVC/ Al) blister (OPA/ Al/ PVC/ Al) blister (OPA/ Al/ PVC/ Al) blister (OPA/ Al/ PVC/ Al) blister (OPA/ Al/ PVC/ Al) blister (OPA/ Al/ PVC/ Al) blister (OPA/ Al/ PVC/ Al) blister (OPA/ Al/ PVC/ Al) blister (OPA/ Al/ PVC/ Al) blister (OPA/ Al/ PVC/ Al) blister (OPA/ Al/ PVC/ Al) blister (OPA/ Al/ PVC/ Al) blister (OPA/ Al/ PVC/ Al) blister (OPA/ Al/ PVC/ Al) blister (OPA/ Al/ PVC/ Al) blister (OPA/ Al/ PVC/ Al) blister (OPA/ Al/ PVC/ Al) blister (OPA/ Al/ PVC/ Al) blister (OPA/ Al/ PVC/ Al) blister (OPA/ Al/ PVC/ Al) blister (OPA/ Al/ PVC/ Al) blister (OPA/ Al/ PVC/ Al) blister (OPA/ Al/ PVC/ Al) blister (OPA/ Al/ PVC/ Al) blister (OPA/ Al/ PVC/ Al) blister (OPA/ Al/ PVC/ Al)
Pretisni omot (OPA/ Al/ PVC/ Al) Pretisni omot (OPA/ Al/ PVC/ Al) Pretisni omot (OPA/ Al/ PVC/ Al) Pretisni omot (OPA/ Al/ PVC/ Al) Pretisni omot (OPA/ Al/ PVC/ Al) Pretisni omot (OPA/ Al/ PVC/ Al) Pretisni omot (OPA/ Al/ PVC/ Al) Pretisni omot (OPA/ Al/ PVC/ Al) Pretisni omot (OPA/ Al/ PVC/ Al) Pretisni omot (OPA/ Al/ PVC/ Al) Pretisni omot (OPA/ Al/ PVC/ Al) Pretisni omot (OPA/ Al/ PVC/ Al) Pretisni omot (OPA/ Al/ PVC/ Al) Pretisni omot (OPA/ Al/ PVC/ Al) Pretisni omot (OPA/ Al/ PVC/ Al) Pretisni omot (OPA/ Al/ PVC/ Al) Pretisni omot (OPA/ Al/ PVC/ Al) Pretisni omot (OPA/ Al/ PVC/ Al) Pretisni omot (OPA/ Al/ PVC/ Al) Pretisni omot (OPA/ Al/ PVC/ Al) Pretisni omot (OPA/ Al/ PVC/ Al) Pretisni omot (OPA/ Al/ PVC/ Al) Pretisni omot (OPA/ Al/ PVC/ Al) Pretisni omot (OPA/ Al/ PVC/ Al) Pretisni omot (OPA/ Al/ PVC/ Al) Pretisni omot (OPA/ Al/ PVC/ Al) Pretisni omot (OPA/ Al/ PVC/ Al) Pretisni omot (OPA/ Al/ PVC/ Al) Pretisni omot (OPA/ Al/ PVC/ Al) Pretisni omot (OPA/ Al/ PVC/ Al) Pretisni omot (OPA/ Al/ PVC/ Al) Pretisni omot (OPA/ Al/ PVC/ Al) Pretisni omot (OPA/ Al/ PVC/ Al) Pretisni omot (OPA/ Al/ PVC/ Al) Pretisni omot (OPA/ Al/ PVC/ Al) Pretisni omot (OPA/ Al/ PVC/ Al) Pretisni omot (OPA/ Al/ PVC/ Al)
1/ 2 EU Number
1/ 2 Številka EU
Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva
Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva Olanzapin Teva